Ipilimumab
Fallopian Tube
Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Fallopian Tube cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enzalutamide Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Mirvetuximab Soravtansine University of Alabama at Birmingham | Phase 2 | CCC |
Nivolumab Memorial Sloan Kettering Cancer Center | Phase 1 | CCC |
Ny-Eso-1 Vaccine Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Abt-767 AbbVie (prior sponsor, Abbott) | Phase 1 | CC |
Carboplatin Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
wt1 vaccine Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →